ASX has a few biotechs involved with wound healing - Avita (AVH) and Factor Therapeutics (FTT) which have not set the world on fire due to regulatory hurdles. This could be a problem for Qbiotics as it seems like they are early stage?
Plus the recent share trades seem to be at $0.40. No idea on how many shares are on issue so hard to say whether it is cheap based on market capitalisation?
- Forums
- Commodities
- Biotech 2017
Biotech 2017, page-64
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online